



Zeal & Innovation in Medicine

Ref No.: ZLL/CS/BSE/NSE

Date: 04.08.2025

BSE Limited, Corporate Relationship Department P. J. Towers, Dalal Street, Mumbai- 400 001 Company Code- 541400	National Stock Exchange of India Limited Listing Compliance Department Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)
---	---

Dear Sir/Madam,

Sub: Press Release for grant of Marketing Authorization for Tamsulosin Hydrochloride and Dutasteride Capsules in Australia

Please find enclosed herewith the Press Release relating to grant of Marketing Authorization for “Tamsulosin Hydrochloride and Dutasteride Capsules” in Australia by the Therapeutic Goods Administration (TGA), to ZIMTAS PTY LTD. (“ZIMTAS”), Subsidiary of the company.

Request you to kindly take the same on your record.

Thanking you,

Yours faithfully,

For ZIM LABORATORIES LIMITED

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972

Encl.: as above

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur
Maharashtra, India. Ph. + 91.718.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960

PRESS RELEASE

ZIM Laboratories Limited has been Granted Marketing Authorization for Tamsulosin + Dutasteride Capsules in Australia

Nagpur, India – August 04, 2025

ZIM Laboratories Limited (the Company) is a research-driven pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments. The Company has state-of-the-art in-house R&D capabilities to offer innovative drug delivery solutions using proprietary technology platforms, aiming to enhance patient convenience and treatment adherence. ZIM Laboratories Limited is listed on the National Stock Exchange of India Limited (NSE) and Bombay Stock Exchange (BSE) Limited.

The Company is pleased to announce that the Therapeutic Goods Administration (TGA), Australia has granted Marketing Authorization (MA) for its Urology product “Tamsulosin Hydrochloride and Dutasteride Capsules” through its Australian subsidiary, ZIMTAS.

This approval marks ZIM’s second Marketing Authorization in Australia and is an important milestone in the Company’s strategy to expand its presence in regulated markets through innovative drug delivery technologies.

Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5-alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men. The fixed-dose combination (FDC) formulation improves patient compliance by combining two essential medications into a single daily dose, offering both rapid symptom relief and long-term disease modification.

This authorization is expected to:

- Facilitate commercial launch in the Australian market via ZIMTAS.
- Support further regulatory submissions in other APAC and international markets.
- Strengthen ZIM’s portfolio in the urology segment with a high-impact combination product.

This achievement aligns with ZIM’s strategy to leverage its development and manufacturing expertise to build a robust pipeline of differentiated generics for global markets.